Patent intelligence · US
US 11123295
Encholeated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections
Encholeated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections
Patent details — US 11123295
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 21, 2021
- Expiration
- Sep 16, 2041
- Applicant
- MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
- Claims
- 17
- CPC classes
- A61K, A61K31/4196, A61K31/496, A61K31/506
Quick answer
US 11123295 (Encholeated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections) is held by MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.. Status: granted. Granted Sep 21, 2021. Expires Sep 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/4196, A61K31/496, A61K31/506, A61K31/513, A61K31/7048
More from MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12409227
Cochleates made with soy phosphatidylserine
granted -
US 11964019
Cochleates made with soy phosphatidylserine
granted -
US 11389407
Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent
granted -
US 10716860
Cochleates made with soy phosphatidylserine
granted -
US 10058521
Omega-3 pentaenoic acid compositions and methods of use
granted -
US 9775907
Cochleates made with soy phosphatidylserine
granted -
US 8906964
Methods of administering compositions comprising docosapentaenoic acid
granted
Frequently asked questions
What is US patent 11123295?
US 11123295 (Encholeated antifungal compounds for central nervous system delivery and treatment of Cryptococcus infections) is held by MATINAS BIOPHARMA NANOTECHNOLOGIES, INC.. Status: granted. Granted Sep 21, 2021. Expires Sep 16, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11123295?
MATINAS BIOPHARMA NANOTECHNOLOGIES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 11123295 expire?
Our index shows an expiration date of Sep 16, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.